Abstract
Dementia, which can be induced by diverse factors, is a clinical syndrome characterized by the decline of cognitive function. Behavioral and psychological symptoms of dementia (BPSD) include depression, agitation, and aggression. Dementia causes a heavy burden on patients and their caregivers. Patients with BPSD should be assessed comprehensively by practitioners and offered appropriate non-pharmacologic and pharmacologic therapy. Nonpharmacologic therapy has been recommended as the basal treatment for BPSD; however, pharmacologic therapy is required under many situations. Medications, including antipsychotic agents, antidepressants, sedative and hypnotic agents, mood stabilizers, cholinesterase inhibitors, and amantadine, are extensively used in clinical practice. We have reviewed the progression of pharmacologic therapy for BPSD.
Keywords: Alzheimer’s disease, antipsychotic, behavioral and psychological symptoms of dementia, dementia, drug, psychiatric symptoms.
Graphical Abstract
Current Neuropharmacology
Title:Drug Therapy for Behavioral and Psychological Symptoms of Dementia
Volume: 14 Issue: 4
Author(s): Feng Wang, Ting-Yi Feng, Shilin Yang, Maurice Preter, Jiang-Ning Zhou and Xiao-Ping Wang
Affiliation:
Keywords: Alzheimer’s disease, antipsychotic, behavioral and psychological symptoms of dementia, dementia, drug, psychiatric symptoms.
Abstract: Dementia, which can be induced by diverse factors, is a clinical syndrome characterized by the decline of cognitive function. Behavioral and psychological symptoms of dementia (BPSD) include depression, agitation, and aggression. Dementia causes a heavy burden on patients and their caregivers. Patients with BPSD should be assessed comprehensively by practitioners and offered appropriate non-pharmacologic and pharmacologic therapy. Nonpharmacologic therapy has been recommended as the basal treatment for BPSD; however, pharmacologic therapy is required under many situations. Medications, including antipsychotic agents, antidepressants, sedative and hypnotic agents, mood stabilizers, cholinesterase inhibitors, and amantadine, are extensively used in clinical practice. We have reviewed the progression of pharmacologic therapy for BPSD.
Export Options
About this article
Cite this article as:
Wang Feng, Feng Ting-Yi, Yang Shilin, Preter Maurice, Zhou Jiang-Ning and Wang Xiao-Ping, Drug Therapy for Behavioral and Psychological Symptoms of Dementia, Current Neuropharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570159X14666151208114232
DOI https://dx.doi.org/10.2174/1570159X14666151208114232 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Quantitative Electroencephalogram Analysis in Parkinson’s Disease
Neuroscience and Biomedical Engineering (Discontinued) Bone Marrow-Derived Mesenchymal Stem Cells Attenuate Amyloid β-Induced Memory Impairment and Apoptosis by Inhibiting Neuronal Cell Death
Current Alzheimer Research Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Recent Patents on Cardiovascular Drug Discovery Angelica Injection Reduces Cognitive Impairment during Chronic Cerebral Hypoperfusion through Brain-Derived Neurotrophic Factor and Nerve Growth Factor
Current Neurovascular Research The Implications of Sortilin/Vps10p Domain Receptors in Neurological and Human Diseases
CNS & Neurological Disorders - Drug Targets Pro-inflammatory Cytokines Modulate Glial Apolipoprotein E Secretion
Current Alzheimer Research Editorial (Thematic Issue: Regulating the CNS Grand Regulator; N-methyl-D-aspartate Receptor-Mediated Neurotransmission)
Current Pharmaceutical Design Lipid Nanoformulations in the Treatment of Neuropsychiatric Diseases: An Approach to Overcome the Blood Brain Barrier
Current Drug Metabolism Machine Learning and Social Network Analysis Applied to Alzheimer's Disease Biomarkers
Current Topics in Medicinal Chemistry Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
Current Pharmaceutical Design Employing New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Current Neurovascular Research Platelet Activation in Alzheimer’s Disease: From Pathophysiology to Clinical Value
Current Vascular Pharmacology Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Patent Selections
Recent Patents on DNA & Gene Sequences Dietary Intake and Physical Activity in a Canadian Population Sample of Male Patients with HIV Infection and Metabolic Abnormalities
Current HIV Research Ramelteon in the Treatment of Delirium: New Perspectives from Reported Findings and a Case Observation
Current Drug Therapy From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer’s Disease
Current Medicinal Chemistry